Restless Leg Syndrome and Parkinson's Disease: Dopamine Deficient States

Scott J. Sherman MD, PhD
Associate Professor of Neurology
The University of Arizona

Restless Leg Syndrome

- Urge to move legs
 - With or without unpleasant sensations
- Worsened with rest
- Improved with activity
- Worsening in the evening or night
- Supportive factors
 - Family Hx
 - Presence of PLMS


Sensory Phenomenon

- Need to move
- Crawling
- Tingling
- Restless
- Cramping
- Creeping
- Pulling

- Painful
- Tension
- Discomfort

Periodic Limb Movements

- Repetitive, stereotyped Video
- Movements occur during sleep



Pathophysiology

- of brain iron stores
- Reduced concentrations NO LOSS OF DOPAMINE PRODUCING NEURONS
- Alterations in brain dopamine systems
- Multiple links between Fe and Dopamine
 - Tyrosine Hydroxylase
 - Thy-1 Adhesion molecule
 - Dopamine-2 receptor

•			
•			
•			

Secondary RLS

- Renal Failure
 - (20-57% in HD patients)
- Iron Deficiency
- Neuropathy
- Pregnancy (26%)
- Other CNS conditions
 - Parkinson Disease
 - Reflects "wearing off" of dopamine replacent meds
- Is Akithesia related to RLS?
 - Fits with dopamine hypothesis

Treatment of RLS

- Dopamine Agonists
 - Ropinerole (™Requip)
 - Pramipexole (™Mirapex) Iron
 - Rotigotine (™Neupro)
 - transdermal
- Anti-epileptics

 - $(\alpha_2\delta$ -blockers of calcium channels)
 - Gabapentin
 - Pregabalin (™Lyrica)

- Opioids
- Benzodiazepines

 - Oral
 - IV iron dextran

Drug	Amount Per Dose (mg)	Duration of Effect (h)	Comment
Dopaminergics:	immediate ef	fect considere	d first line therapy
L-dopa	100-250	2-6	Approved in Europe, fast onset, can use as needed, highest augmentation rates
Pramipexole	0.125-1	5-12	Approved, commonly used, slower onset but longer duration
Ropinirole	0.25-4	4-8	Approved, slow release preparations available
Pergolide	0.125-1	6-14	Well studied but seldom used because of the ris for cardiac valve fibrosis and other possible ergot AEs
Cabergoline	0.25-2	>24	Long acting but may have same AEs as other ergot DAs
Rotigotine	0.5-6	24	Patch preparation, well studied and effective in RLS
Bromocriptine	5-20	4-6	Rarely used in RLS
Opioids: numer	ous opioids an	r used	
Methadone	2-15	8-12	Latency to benefit
Hydrocodone	5-10	4-10	Faster acting, shorter duration
Alpha-2 delta b	lockers		
Gabapentin	300-1200	4-8	May help painful component of RLS
Pregabalin	50-200	6-12	Trials underway but almost no published data
Gabapentin enacarbil	600-12,000	8-16	Gabapentin prodrug with better absorption an pK profile. Well studied and effective
			than RLS, can be used in combination with othe is traditionally used.
Oral iron	>50	?	No specific iron salt is superior, titrate up as tolerated. Ferritin will only modestly increas
IV iron dextran	19	7	Usually not repeated before 3 months, several day latency to benefit, long-term safety unknown, patients with "normal" serum feetings.

William G . Ondo Neurol Clin 27 (2009) 9779-799

Treatment Complications

- Augmentation (48%)
 - Phase shift
 - Dose escalation
- Drug Side Effects
- Dopamine agonists
 - Nausea
 - Rare but must monitor
 - Compulsive behaviors
 - "Sleep attacks"

Diagnosis of RLS


- Differential Diagnosis
 - Peripheral Neuropathy
 - Akathisia
 - Nocturnal Leg Cramps
 - Secondary RLS
 - "painful legs and moving toes" syndrome
- Ferritin and iron studies
- Electrolytes
- Optional Studies
 - (particularly when there is NO family hx)
 - NCV/EMG to r/o neuropathy
 - Polysomnography


PD: Clinical Features/Cardinal Signs

- 1817: James Parkinson "An Essay on the Shaking Palsy"
- Onset
 - mean PS 61.6 years; PD 62.4 years
 - rare before age 30; 4-10% cases before age 40
- Affect 1% of the population over 60 years of age

Early Signs and Symptoms • Cardinal Characteristics • Other Resting tremor - Micrographia Bradykinesia Masked face - Rigidity - Stooped, shuffling gait Postural instability - Decreased arm swing when walking Additional Signs and Symptoms • Difficulty arising from a chair • Difficulty turning in bed • Hypophonic speech • Sialorrhea • Loss of the sense of smell • Foot dystonia Criteria for Diagnosis • At least two of three: rest tremor, bradykinesia, rigidity • Absence of a secondary cause—drugs, metabolic, • Definitive diagnosis can only be made by autopsy • Pragmatic approach: response to dopamine replacement therapy May want to avoid early use of levodopa in younger patients

Pathology of Parkinson's Disease







Drug Classes in PD

- Dopaminergic agents
 - Dopamine agonists
 - Levodopa
 - COMT inhibitors
- MAO-B inhibitors
- Anticholinergics
- Amantadine

Reducing the Peripheral Metabolism of Levodopa

Addition of a COMT Inhibitor Decreases Conversion of Levodopa to 3-OMD in the Periphery






$$\label{eq:decomposition} \begin{split} & DDC = dopa\ decarboxylase;\ 3-OMD = 3-O-methyldopa;\ BBB = blood-brain\ barrier;\ & COMT = cathechol-O-methyltranserase. \end{split}$$

Levodopa/Carbidopa Formulations

	Onset	Duration
Immediate Release 10/100, 25/100, 25/250	20-40 min	2-4 hr
Controlled Release 25/100, 50/200	30-60 min	3-6 hr
TMStalevo 50, 75,100,125, 150 Triple combination Carbidopa/levodopa/enta	20-40 min	3-5 hr




Benefits of Dopamine Agonists

- Direct receptor stimulation
 - does not require conversion to dopamine
 - does not add additional oxidative stress to remaining nigral neurons
- Delay onset of dyskinesia
- Decrease pulsatile stimulation
- May have a neuroprotective effect

Dopamineregic Drugs 6-24 mg/day Ropinirole TID (for PD) 0.5-3 mg/night Requip XL qd same same (?) Pramipexole TID (for PD) 0.75-4.5 mg/day 0.125-1 mg/night Mirapex ER QD Same (?) same Rotigotine QD, transdermal 2-8 mg/day Not approved (?) TID- q2hr (PD) 300-1200 mg/day 100-250mg/night Levodopa

DAs: Common Adverse Effects

- Nausea, vomiting
- Dizziness, postural hypotension, peripheral edema
- Drowsiness & somnolence, SLEEP ATTACKS
- Confusion, hallucinations
- COPULSIVE BEHAVIOR
 - Gambling, sexual addiction, compulsive eating



Comparison of RLS vs PD

	Parkinson Disease	Restless Leg
Dopamine dysregulation	+++	+++
Iron Dysregulation	?+	++
Dopaminergic cell loss	+++	-
Dopamine agonist response	++	+++
Levodopa response	+++	++
Family history/genetic component	+/-	+++
Primarily Clinical Dx	+++	+++